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We examined adenomas and cancers from hereditary non-polyposis colorectal cancer (HNPCC) syndrome patients for the
presence of frameshift mutations in the smooth-muscle myosin gene, MYH11. Our results show that mutations in MYH11 occur
more frequently in cancers than adenomas (P¼0.008) and are dependent on microsatellite instability (MSIþ).
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DNA microsatellite instability (MSIþ) is a hallmark of tumours
where there is loss of a mismatch repair (MMR) protein. This is
exemplified in patients with hereditary non-polyposis colorectal
cancer (HNPCC), an autosomal-dominant syndrome defined by
predisposition to colorectal cancer (CRC; 2–5% of all incident
cases) and to other cancers, including endometrial, stomach and
ovarian cancer. Genetically, HNPCC is characterised by germline
mutation and somatic inactivation of the MMR genes (Liu et al,
1996; Lynch and Smyrk 1996; Lagerstedt Robinson et al, 2007).
MSIþ CRCs also account for approximately 15% of all sporadic
cases. Microsatellites have been characterised as being prone to
frameshift mutations in MSIþ cancers and mutations in coding
regions of genes such as TGFbRII, BAX, and MSH6, have
been implicated in contributing to the neoplasia phenotype
(Johannsdottir et al, 2000).
The genetic pathways of colorectal tumorigenesis in HNPCC and
sporadic MSIþ CRCs may overlap. Indeed, much of what we
know about HNPCC has been conflated with that of the more
common sporadic MSIþ CRCs. However, there are a number of
important differences, particularly with regard to K-RAS, BRAF,
and b-catenin mutational frequencies (Johnson et al, 2005a,b;
Loughrey et al, 2007). Recently, the SM2 isoform of the smooth-
muscle myosin gene, (MYH11) was implicated in human intestinal
neoplasia. Somatic frameshift mutations at a coding region
containing a repeat of eight cytosines, (C)8, in the final exon of
MYH11 were identified in sporadic MSIþ cancers and a germline
frameshift mutation was also described in a Peutz–Jeghers
syndrome patient (Alhopuro et al, 2008). To establish the
contribution, timing and frequency of the MYH11 frameshift
mutation in HNPCC tumorigenesis, we analysed a series of
adenomas and cancers from HNPCC patients.
MATERIALS AND METHODS
Patients
Hereditary non-polyposis colorectal cancer was diagnosed based
on previously reported criteria and national ethics guidelines were
followed (Johnson et al, 2005a,b). A total of 77 HNPCC individuals
from 60 families were selected and 34 adenomas plus 53 CRCs
collected. Cancers were obtained from the distal and proximal
colon and all grade from poor to well-differentiated and Duke
stages A–C were represented as well as tumours that had
metastasised to distant sites (D). Four endometrial cancers were
also investigated. Hereditary non-polyposis colorectal cancer
matched normal tissue was available for 41 samples.
Mutation analysis
DNA was prepared by dissection of neoplastic and normal areas
from paraffin-embedded tissue followed by a proteinase K
digestion. MSI status was defined using microsatellite markers
BAT-25, BAT-26, D2S123, D5S346, and D17S250 analysed on an
ABI-3100 genetic analyzer and classified as MSIþ as per Bethesda
guidelines (Boland et al, 1998).
The MYH11 mutation was examined using labelled primers
flanking the (C)8 tract (accession no. NM_022844; nucleotide nos.
5898–5905) and analysed on an ABI-3100 genetic analyser.
Detected mutations were verified using direct sequencing.
Frequency of frameshift mutations at intronic (C)8 tracts were
determined with primer pairs flanking regions in DHX30, DDELF1,
ILIR2 and PAK3 genes (Alhopuro et al, 2008). Primer details are
available on request.
Statistics
Fisher’s exact test was used to test for significance using Stata 8.2
(statistical software release 8.0; Stata corporation College Station,
TX, USA).
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The (C)8 repeat tract in the last exon of the SM2 isoform of MYH11
was examined in 87 HNPCC intestinal tumours. MSIþ adenomas
had a mutation rate of 5% (1/20) with a single adenoma carrying a
frameshift mutation in one allele (Table 1). In contrast to MSIþ
adenomas, MSIþ cancers had a much higher rate of frameshift
mutation (36%, 17 out of 47; P¼0.008; Table 1). There were fewer
mutations in our HNPCC MSIþ cancers (36%) compared with the
sporadic MSIþ cancers (55%) reported by Alhopuro et al (2008)
and this difference was significant (P¼0.04). We also investigated
four MSIþ endometrial cancers and found MYH11 frameshift
mutations in 50% of samples (2 out of 4; Table 1). No frameshift
mutations were found in the matched normal DNA (n¼41) from
HNPCC patients, confirming the somatic origin of mutations.
There were also no mutations found in microsatellite stable
(MSI ) adenomas (n¼14) or MSI  cancers (n¼6; Table 1).
A concern when analysing allele mutation frequency in MSIþ
tumours is the confounding issue of passenger mutations that do
not contribute to neoplasia. We assessed mutation frequency at
four loci containing intronic (C)8 repeat tracts in which any
frameshift mutation would not be predicted to be selected for and
would therefore represent passenger mutations (Alhopuro et al,
2008). We found that mutation frequencies at the intronic (C)8
repeats were higher in HNPCC MSIþ cancers (16% of all loci, 29
out of 179) as compared with MSIþ adenomas (7% of all loci, 5
out of 69; P¼0.07) indicating increased passenger mutation rates
in the MSIþ CRCs. More importantly, MSIþ cancers had
significantly higher frameshift mutation rates in MYH11 than at
the intronic repeats (36 vs 16%, P¼0.004). MSIþ adenomas
however, displayed no difference between frequency of MYH11
(5%, 1 out of 20) and intronic (C)8 frameshift mutations (7%, 5 out
of 69; P¼1.0) These results indicate that frameshift mutations at
MYH11 do not play a role in early stages of tumour formation, but
are likely to play a role in progression of HNPCC tumorigenesis.
We next investigated whether there were associations between
the presence of an MYH11 mutation and pathological features such
as Dukes stage, tumour grade and tumour site. Dukes stage was
available for 33 cancers (Dukes AþB, n¼21; Dukes CþD, n¼12)
and frameshift mutations were found in 29% (6 out of 21) of the
AþBs and 25% (3 out of 12) of the CþDs indicating that
mutation frequency was not increased in the more advanced Dukes
stage (P¼1.0; Table 2). A total of 29 cancers had tumour grade
available and although the numbers in the well- and poorly
differentiated grades were small, there was a trend towards an
increase in mutation frequency with grade (well differentiated, 0%,
0 out of 3; moderately, 27%, 6 out of 22; poorly differentiated, 50%,
2 out of 4; Table 2), but this was not significant (P¼0.4). Mutation
frequency was not influenced by site of tumour presentation, distal
or proximal (P¼1.0; Table 2).
In conclusion, our results indicate that the MYH11 mutation is
not required for early HNPCC adenoma formation, but it is
selected for in the process of MSIþ cancer tumorigenesis. The role
of MYH11 in the development of MSIþ cancers merits further
investigation particularly with respect to the underlying molecular
and cellular mechanism.
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